Roche Holding AG


  • NORWICH, England, Aug 17- Pampering leafcutter ants with fragrant rose petals and fresh oranges may seem an unlikely way to rescue modern medicine, but scientists at a lab in eastern England think it's well worth trying.

  • Chugai denies talks with Roche regarding a takeover Saturday, 16 Aug 2014 | 10:26 PM ET

    TOKYO, Aug 17- Chugai Pharmaceutical Co Ltd has denied a media report saying Roche Holding AG is in talks to buy the almost 40 percent stake in the Japanese company that it does not already own for about $10 billion. The Japanese firm, in a news release late on Saturday, said the media report "is not based on any announcement made by Chugai or Roche."

  • *VIX jumps on Russia, Ukraine concerns. NEW YORK, Aug 15- U.S. stocks ended mixed on Friday, paring an earlier selloff sparked by reports of Ukraine shelling a Russian armored column.

  • Stocks close mixed on renewed geopolitical concerns Friday, 15 Aug 2014 | 4:49 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks ended the week mixed after news of fresh conflict between Russia and Ukraine.

  • Friday's midday movers: Dillard's, Deere & more Friday, 15 Aug 2014 | 12:50 PM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Take a look at some of Friday's midday movers:

  • A spokeswoman for Roche declined to comment on the report. There has long been speculation that Roche might swallow Chugai- following a similar buyout of U.S. biotech group Genentech in 2009- to maximise exposure to the Japanese drugs market, the world's second largest after the United States.

  • Aug 15- Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi.

  • Roche to offer $10 bln for rest of Chugai - Bloomberg Friday, 15 Aug 2014 | 11:33 AM ET

    Aug 15- Roche Holding AG is in talks to buy the almost 40 percent stake in Japan's Chugai Pharmaceutical Co Ltd that it does not already own for about $10 billion, Bloomberg reported, citing people familiar with the matter.

  • Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.

  • Gilead says wins favorable ruling on hep C drug Friday, 15 Aug 2014 | 8:10 AM ET

    Aug 15- Gilead Sciences Inc said an arbitration panel has ruled in its favor, rejecting patent infringement claims from Roche Holding AG, related to Gilead's hepatitis C drug, Sovaldi.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • Aug 1- Biota Pharmaceuticals Inc said its influenza treatment failed to meet the main goal in a mid-stage study, about two months after the company lost a key government contract supporting the drug's development.

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • FDA OKs expanded use of Regeneron's eye drug Tuesday, 29 Jul 2014 | 10:29 PM ET

    Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.

  • BEIJING, July 28- Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • Europe shares close higher on PMI data, bank gains Thursday, 24 Jul 2014 | 11:47 AM ET

    European shares closed higher on Thursday, after a business activity index showed the euro zone rebounded in July.

  • BASEL, July 24- Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.